Long-term follow-up for people treated with inaticabtagene autoleucel

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational program enrolls patients who previously received at least one infusion of inaticabtagene autoleucel, including those from prior clinical trials and commercial use. Participants re-consent and are followed once a year for up to 15 years after infusion to collect safety data, medical history, disease status, and any late adverse events. No new treatments are assigned; data are collected during routine clinic visits or scheduled follow-up assessments. The collected information is intended to characterize long-term safety after the product's commercialization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Agree to sign an informed consent form for long-term follow-up studies.
2. Registered clinical trial patients with different indications for this product who have received at least one infusion of Inaticabtagene Autoleucel Injection in the past, as well as post market commercialized patients.

Exclusion Criteria:

\- None.

Where it's running

• Institute of Hematology & Blood Diseases Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Jianxiang Wang, Dr. — Institute of Hematology & Blood Diseases Hospital, Tianjin, China
• Study coordinator: Yinling Wu
• Email: wuyinling@juventas.cn
• Phone: +86 13161292425

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding resistance to chemo-immunotherapy in aggressive lung cancers

  This study is trying to understand why some adults with aggressive lung cancers don’t respond to chemo-immunotherapy, so they can find better treatment options for these patients.

  Recruiting Oncology Center of Biochemical Education And Research · New York, New York and 1 other locations · NCT06717243

• Combining ziftomenib and imatinib for advanced gastrointestinal stromal tumors

  This study is testing whether combining two medications, ziftomenib and imatinib, can help adults with advanced gastrointestinal stromal tumors who haven't responded well to imatinib alone.

  Recruiting at 32 sites Phase 1 Kura Oncology, Inc. · Birmingham, Alabama and 31 other locations · NCT06655246

• Dornase alfa plus cisplatin for refractory germ cell cancer

  This trial will test whether adding dornase alfa to cisplatin helps adult men with relapsed or refractory germ cell tumors who have failed prior chemotherapy.

  Recruiting Phase 2 National Cancer Institute, Slovakia · Bratislava · NCT07121322

• Natural history of DICER1-related cancer predisposition syndrome

  This study is trying to learn more about people with rare tumors linked to DICER1 mutations to see how common these genetic changes are and understand the types of tumors they cause.

  Recruiting at 2 sites National Institutes of Health Clinical Center (CC) · Bethesda, Maryland and 1 other locations · NCT01247597

• Elacestrant for ER-positive uterine sarcomas

  This trial tests whether the oral drug elacestrant can slow or stop growth in people with advanced estrogen receptor–positive uterine sarcomas.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07467772

• Using engineered immune cells with chemotherapy to treat blood cancers

  This study is testing if using special immune cells along with chemotherapy can help people with tough-to-treat blood cancers like B-cell lymphoma and leukemia feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05092451

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.